10:12 EST SAB Biotherapeutics (SABS) files $300M mixed securities shelf
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics Launches New $75 Million ATM Program
- SAB Biotherapeutics: Favorable SAB-142 Safety Profile and De-Risked Phase 2b Design Underpin Buy Rating
- SAB Biotherapeutics initiated with a Buy at Guggenheim
- SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial
- SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint